Saliency's platform uses proprietary algorithms to build and train AI models quickly from a small number of deidentified images. The models can be used to screen, redact, or interpret medical images to support numerous therapeutic areas.

The AI capability will be embedded into Bioclinica's current and future imaging products and services for research sponsors and clinical research organizations.

Emedgene, Illumina partner on rare disease analysis
Emedgene and Illumina have partnered to interpret genomic data for rare diseases.

Google's DeepMind makes a quantum leap in solving the protein folding problem
Artificial intelligence has made something of a breakthrough in the prediction of protein structures. The results came about as part of the 14th Critical...